Showing 1901-1910 of 6037 results for "".
- Ocular Therapeutix Announces Early Assignment of Permanent and Specific J-Code for Dextenzahttps://modernod.com/news/ocular-therapeutix-announces-early-assignment-of-permanent-and-specific-j-code-for-dextenza/2476773/Ocular Therapeutix announced that the Centers for Medicare and Medicaid Services (CMS) has assigned a specific and permanent reimbursement J-code through the Healthcare Common Procedure Coding System (HCPCS) for Dextenza (dexamethasone ophthalmic insert) 0.4 mg, which is approved for the
- Goldman Sachs Unit to Buy 575 Optometry Practices in $2.7 Billion Dealhttps://modernod.com/news/report-goldman-sachs-unit-to-buy-capital-vision-services-in-2-7-billion-deal/2476625/In one of the largest optometry deals to date, the merchant-banking division of Goldman Sachs Group (West Street Capital Partners VII) announced that it is buying Capital Vision Services, which operates 575 optometry practices, from private-equity firm Altas Partners LP and Canadian pension fund
- Ocular Therapeutix Announces Receipt of C-Code and Pass-Through Payment Status for Dextenzahttps://modernod.com/news/ocular-therapeutix-announces-receipt-of-c-code-and-pass-through-payment-status-for-dextenza/2476614/Ocular Therapeutix announced that the Centers for Medicare and Medicaid Services (CMS) has approved transitional pass-through payment status and established a new reimbursement code for Dextenza (dexamethasone ophthalmic insert). The code, C9048, is scheduled to become effective July 1, 2019.
- EyePoint Pharmaceuticals Announces Assignment of Permanent J-Code for Dexycu by CMShttps://modernod.com/news/eyepoint-pharmaceuticals-announces-assignment-of-permanent-j-code-for-dexycu-by-the-center-for-medicare-and-medicaid-services-cms/2479679/EyePoint Pharmaceuticals announced that the Centers for Medicare and Medicaid Services (CMS) has assigned a specific and permanent reimbursement J-code through the Healthcare Common Procedure Coding System (HCPCS) for Dexycu (dexamethasone intraocular suspension) 9%. Dexycu is the first and only
- CMS Issues Preliminary Decision on Unique J Code for Avedro Photrexa Drug Formulationshttps://modernod.com/news/cms-issues-preliminary-decision-on-unique-j-code-for-avedro-photrexa-drug-formulations/2480101/Avedro announced that the Centers for Medicare and Medicaid Services (CMS) has issued a preliminary decision to establish a product specific Healthcare Common Procedure Coding System (HCPCS) J code for Photrexa drug formulations. Claims submitted with a product specific J code are generally proce
- WAVE Eye Care Announces New Integration Between Topcon MYAH and WAVE Lens Designer Softwarehttps://modernod.com/news/wave-eye-care-announces-new-integration-between-topcon-myah-and-wave-lens-designer-software/2485329/At the Global Specialty Lens Symposium (GSLS) in Las Vegas, WAVE Eye Care announced a integration between the Topcon MYAH and WAVE Lens Designer Software designed to streamline the specialty contact lens fitting and design process for eye care practitioners.
- Cognition Therapeutics Reports Topline Results Showing Oral Zervimesine Reduced Lesion Growth in Phase 2 Study in GAhttps://modernod.com/news/cognition-therapeutics-reports-topline-results-showing-oral-zervimesine-reduced-lesion-growth-in-phase-2-study-in-ga/2482793/Cognition Therapeutics reported topline results from the Phase 2 COG2201 ‘MAGNIFY’ trial of zervimesine (CT1812) in adults with geographic atrophy (GA). The results show zervimesine-treated participants had 28.6% slower GA lesion growth on average and at 18 months, and their lesi
- Zeiss Launches Micor 700 Lens Extraction Devicehttps://modernod.com/news/zeiss-launches-micor-700-lens-extraction-device/2482459/Zeiss announced the US launch of the Micor 700 lens extraction device, which is designed to eliminate the need for ultrasound, offering a more sustainable and cost-effective solution while expanding the intraocular working space for surgeons. The Micor 700 will debut
- Cliara Awarded US Patent for Contact Lens Force Measurement Devicehttps://modernod.com/news/cliara-awarded-us-patent-for-contact-lens-force-measurement-device/2482179/Cliara has been granted a United States patent for a device designed to accurately measure the force required to remove gas-permeable contact lenses from the eye, according to a company news release. Cliara LLC is collaborating with BostonSight and LV Prasad Eye Institute
- SightGlass Vision Receives FDA Breakthrough Device Designation for Myopia Spectacle Lenshttps://modernod.com/news/sightglass-vision-receives-fda-breakthrough-device-designation/2482118/The FDA has granted Breakthrough Device designation to SightGlass Vision's Diffusion Optics Technology (DOT) spectacle lenses, which are intended to slow myopia progression in children. The design is the first to use the contrast management mechanism of action, incorporating thousan